The deadly virus has caused a 12% spike in COVID-19 cases with the shocking total number of cases to hit 1,03,95,278 in India. The increment in fresh cases by 20,346 since yesterday raised alarms. In the past 24 hours, number of deaths has reported to be increased by 222 which raised the total number of deaths to be 1,50,336. Maharashtra has been worst hit with 4,382 new coronavirus cases and 66 deaths in a day. Other most severely affected states are Karnataka, Andhra Pradesh, Kerala and Tamil Nadu with most fresh cases and death tolls.
Our government is working vigorously to control the situation at the earliest possible. Two firms namely Bharat Biotech and Serum Institute of India has been given the permission to conduct mass inoculation in the country. Bharat Biotech has enrolled 25,800 volunteers to conduct the phase 3 clinical trial of its vaccine namely Covaxin. The other vaccine manufactured by SII is Oxford-AstraZeneca's Covishield.
In a press briefing on January 5, Dr Krishna Ella, chairman of Bharat Biotech said “ We don't deserve this backlash “ on the critics & questioning of the the covaxin efficacy.
The 3rd phase of Covaxin’s efficacy trial had started from November after the two successful trial phases.